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Background: E-cadherin methylation is important in gastric carcinogenesis. Reversing hypermethylation
may halt the carcinogenic process. We have previously reported that Helicobacter pylori infection is
associated with E-cadherin methylation in chronic gastritis patients.
Aim: To examine if eradication of H pylori could reverse E-cadherin methylation.
Methods: Patients with dyspepsia and positive for H pylori infection, with a mucosal biopsy showing
chronic active gastritis, were randomised to receive H pylori eradication therapy (group 1, n = 41) or no
treatment (group 2, n = 40), and were followed up prospectively. Gastric mucosae were taken for
methylation assay at week 0 (before treatment) and week 6 (after treatment). Archived specimens of
intestinal metaplasia with H pylori infection (n = 22) and without (n = 19) were retrieved for methylation
analysis. Methylation was assessed using methylation specific polymerase chain reaction and sequencing.
Results: Methylation at E-cadherin was detected in 46% (19/41) and 17% (7/41) of patients at weeks 0
and 6, respectively, in group 1 (p = 0.004); 78.9% (15/19) of specimens were unmethylated after
eradication of H pylori. Mucosal biopsy showed chronic inactive gastritis in 35 patients, intestinal
metaplasia in one, and normal mucosa in five at week 6. Methylation was detected in 47.5% (19/40) and
52.5% (21/40) of patients at weeks 0 and 6, respectively, in group 2 (P = 0.5). Gastric mucosal biopsy
showed persistent chronic active gastritis in all cases. Methylation frequency did not differ in H pylori
positive or negative intestinal metaplastic specimens (72.7% v 63%; p = 0.5).
Conclusion: H pylori eradication therapy could reverse methylation in patients with chronic gastritis. This
demonstrates an environmental effect on methylation.
G
astric carcinogenesis is a multistep process involving
multiple genetic and epigenetic events, with a
postulated intestinal metaplasia-dysplasia-invasive
carcinoma sequence during morphologic progression.1
Helicobacter pylori infection is an important aetiological risk
factor in gastric cancer, and has been classified as a group I or
definite carcinogen by the World Health Organisation’s
International Agency for Research on Cancer.2
E-cadherin is an adhesion molecule that is expressed on all
epithelial cells.3 4 It is an important tumour suppressor and
invasion suppressor gene. In gastric carcinogenesis, the
critical role of E-cadherin is underlined by the observation
that familial gastric cancer is related to germline mutations of
the E-cadherin gene.5 6 Furthermore, somatic mutations of
E-cadherin were found in approximately 50% of gastric
carcinomas of the diffuse histological type.7 Finally, in
two kindreds with familial gastric cancer and germline
E-cadherin mutation, promoter CpG hypermethylation
was found to be the second ‘‘genetic hit’’ in abrogating
E-cadherin expression.8 It is now increasingly recognised
that epigenetic silencing of gene expression by promoter
CpG hypermethylation is an important alternative mechan-
ism in inactivating tumour suppressor genes and tumour
associated genes in cancers,9 10 and in gastric cancer and its
precursors.11 12
We have previously shown that expression of E-cadherin
protein was decreased early in precancerous lesions of gastric
cancer, suggesting E-cadherin may play an early role in
gastric cancer.13 Methylation of E-cadherin was identified
early in precancerous lesions of gastric cancer, being found in
31% of gastric mucosa with chronic gastritis.14 More
importantly, H pylori was an independent risk factor
associated with methylation of E-cadherin in non-lesional
gastric mucosa from patients with dyspepsia.14
Targeting epigenetic changes that occur before the devel-
opment of frank malignancy as chemopreventive interven-
tion offers the maximal impact.10 15 Hence in gastric cancer,
early reversal of promoter methylation at precanerous lesions
before the development of frank gastric cancer might halt
gastric carcinogenesis. We hypothesised that H pylori infec-
tion may be an important aetiology in causing methylation at
E-cadherin and that eradication of H pylori might reverse
methylation at E-cadherin. We tested this hypothesis by
examining methylation of the E-cadherin gene in gastric
mucosa with chronic gastritis from patients without gastric
cancer before and after eradication of H pylori, and also in
intestinal metaplasia from patients with and without H pylori
infection.
MATERIALS AND METHODS
Patients and specimens
Two cohorts of patients were studied. The first cohort, which
constituted the majority of patients in this study, was derived
from a prospective randomised controlled study. Ninety
patients from the Department of Medicine, Queen Mary
Hospital, Hong Kong, who had upper endoscopy for
investigation of dyspepsia and were confirmed to be H pylori
positive were recruited to the study. The presence of H pylori
infection was confirmed by rapid urease test and subsequent
histological analysis using both haematoxylin-eosin and the
modified Giemsa stains. Equivocal cases were excluded from
Abbreviations: PCR, polymerase chain reaction; MSP, methylation
specific polymerase chain reaction
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the analysis. This approach has been validated previously in
our centre.16 Antral gastric mucosal biopsies were taken for
histological analysis, E-cadherin immunohistochemical
staining, and methylation study (week 0). Haematoxylin-
eosin stained slides were evaluated for the presence of
chronic gastritis, intestinal metaplasia, or dysplasia.
Histological assessment was categorised according to the
Sydney classification.
Patients were included in the study only if the gastric
mucosal histology showed chronic active gastritis after
confirmation of H pylori infection. Patients were then
randomised into two groups: group 1 subjects received H
pylori eradication therapy while group 2 received no treat-
ment. H pylori eradication therapy consisted of one week of
amoxicillin 1000 mg twice/day, clarithromycin 500 mg twice/
day, and omeprazole 20 mg twice/day. All patients were
followed up prospectively for six weeks. Upper endoscopy
was repeated again at the end of six weeks (week 6). The
status of H pylori infection was reassessed using the same
method. Antral gastric mucosal biopsies were again taken for
histology, immunostaining, and methylation analysis.
In order to assess the degree of concordant methylation at
the antrum, five additional random antral mucosa biopsies
were taken from each of the 10 patients at week 0.
Concordant methylation was defined as the same methyla-
tion status (either negative or positive) at the E-cadherin
gene in at least four biopsy samples in each patient. Informed
consent for tissue procurement was obtained from all
patients.
The second cohort comprised archival antral biopsy speci-
mens with documented intestinal metaplasia from patients
who were H pylori positive (n = 22) and from those who were
H pylori negative (n = 19) as controls. The study was
approved by our institutional review board.
Methylation specific polymerase chain reaction (MSP)
Gastric mucosal tissue was obtained by microdissection from
5 mm thick haematoxylin- eosin stained, paraffin embedded
tissue sections without a coverslip, followed by DNA
extraction, as described previously.17 The methylation status
of the E-cadherin promoter was determined by bisulfite
treatment of DNA followed by MSP, as described previously.18
MSP was performed by an operator unaware of the clinical
data of the specimens. Briefly, 2 mg of DNA were denatured
with 2 M NaOH at 37 C˚ for 10 minutes, followed by
incubation with 3 M sodium bisulfite, pH 5.0, at 50 C˚ for
16 hours. Bisulfite treated DNA was then purified (DNA
Cleanup Kit; Promega, Madison, Wisconsin, USA), incubated
with 3 M NaOH at room temperature for five minutes,
precipitated with 10 M ammonium acetate and 100%
ethanol, washed with 70% ethanol, and resuspended in
20 ml of distilled water. DNA (2 mm) was then amplified for
the E-cadherin gene by polymerase chain reaction (PCR)
with the primers described by Herman and colleagues
(table 1).18 CpGenome Universal Methylated DNA
(Intergen, Purchase, New York, USA) and reagent blanks
were used as positive and negative controls in each
experiment. All tests were performed in duplicate. For
confirmation of the specificity of the MSP, PCR products
from the methylated and unmethylated primers were gel
purified and sequenced, as previously described.19
Pre- and post-H pylori eradication methylation pattern was
also assessed in 10 additional pairs of biopsy specimens from
group 1 at DAP kinase (DAPK), O6-methyl-guanine methyl-
transferase (MGMT), human Mut L homologue (hMLH1),
p16 genes,20 and oestrogen receptor beta (table 1).21
Immunohistochemical staining for E-cadherin
E-cadherin expression was examined by immunostaining
using the avidin-biotin complex immunoperoxidase method,
as described previously.13 Briefly, 4 mm thick tissue slides
were deparaffinised in xylene and rehydrated serially with
alcohol and water. Endogenous peroxidase was blocked with
3% hydrogen peroxide for 10 minutes, followed by micro-
wave antigen retrieval for nine minutes at 95 C˚ in 10 mM
sodium citrate buffer, pH 6.0. Slides were then incubated
with an avidin conjugated monoclonal anti-E-cadherin anti-
body (HECD-1, 1:500 dilution in phosphate buffered saline;
Zymed Laboratories Inc., South San Francisco, USA) in a
moist chamber at 37 C˚ for one hour. Bound antibody was
detected by a biotinylated secondary antibody and the avidin-
biotin complex immunoperoxidase method (Dako Corp.,
Carpinteria, California, USA). Slides were finally counter-
stained with Mayer’s haematoxylin. As a negative control,
the primary antibody was replaced with mouse IgG. Slides
with normal colonic mucosa were used as positive controls.
E-cadherin staining was classified as altered when cytoplas-
mic and/or membranous staining was reduced or absent.
Statistical analysis
The x2 test was used to compare categorical associations and
the Student’s t test for continuous associations. Two sided
tests were used to calculate p values.
RESULTS
Demographic data from patients who presented with
dyspepsia
Two patients from the first cohort were excluded from the
study because the initial gastric mucosal biopsies showed
evidence of intestinal metaplasia. The remaining 88 patients
were randomised into groups 1 and 2. Three patients from
group 1 and four patients from group 2 defaulted for the
second upper endoscopy and were excluded from the final
Table 1 Primers and polymerase chain reaction conditions for E-cadherin, DAPK, MGMT, hMLH1, p16, and OR beta
Locus Allele Sense primers Antisense primers
Annealing
temp ( C˚)
E-cadherin Methylated 599- TTAGGTTAGAGGGTTATCGCGT -39 59- TAACTAAAAATTCACCTACCGAC-39 57
Unmethylated 59- TAATTTTAGGTTAGAGGGTTATTGT-39 59- CACAACCAATCAACAACACA-39 53
DAPK Methylated 59- GGATAGTCGGATCGAGTTAACGTC -39 59- CCCTCCCAAACGCCGA -39 60
Unmethylated 59-GGAGGATAGTTGGATTGAGTTAATGTT -39 59- CAAATCCCTCCCAAACACCAA -39 60
MGMT Methylated 59- TTTCGACGTTCGTAGGTTTTCGC -39 59- GCACTCTTCCGAAAACGAAACG -39 59
Unmethylated 59-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-39 59-AACTCCACACTCTTCCAAAAACAAAACA-39 59
hMLH1 Methylated 59- TATATCGTTCGTAGTATTCGTGT -39 59- TCCGACCCGAATAAACCCAA-39 60
Unmethylated 59- TTTTGATGTAGATGTTTTATTAGGGTTGT -39 59- ACCACCTCATCATAACTACCCACA -39 60
p16 Methylated 59-TTATTAGAGGGTGGGGCGGATCGC-39 59-GACCCCGAACCGCGACCGTAA-39 65
Unmethylated 59-TTATTAGAGGGTGGGGTGGATTGT-39 59-CAACCCCAAACCACAACCATAA-39 60
OR beta Methylated 59-TTTGGAAGGTGGGTTTGGTC-39 59-CGCATACAAATATAATAACTAACG-39 49
Unmethylated 59-TTTGGAAGGTGGGTTTGGTT-39 59-CACATACAAATATAATAACTAACA-39 45
DAPK, DAP kinase; MGMT, O6-methyl-guanine methyltransferase; hMLH1, human Mut L homologue; OR beta, oestrogen receptor beta.
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analysis. There were nine men and 32 women in group 1 and
11 men and 29 women in group 2 (p = 0.6). Mean age of
group 1 patients was 51 (11) years and 47 (16) years in group
2 (p = 0.2).
Promoter methylation at E-cadherin at week 0 and
week 6 in group 1 patients
At week 0, chronic active gastritis was present in all
specimens. Promoter methylation at E-cadherin was present
in 46% (19/41) of the gastric mucosa specimens (examples in
fig 1A). There was no difference in mean age between
patients who had methylation in their gastric mucosa (51
(9) years) and those who had not (51 (11) years) (p = 0.8).
At week 6 after H pylori eradication therapy, none of the
patients showed persistent H pylori infection. Normal
histology was observed in the antral gastric biopsy specimens
from five patients, while 35 biopsy specimens showed chronic
inactive gastritis, and one specimen showed intestinal
metaplasia (fig 2). Promoter methylation at E-cadherin was
only present in 17% (7/41) of the gastric mucosa specimens,
which was significantly different from that in the pre-
eradication specimens (p = 0.004) (table 2; examples in
fig 1B)—that is, among the 19 specimens which were
positively methylated before H pylori eradication, 15 (78.9%)
became unmethylated after eradication therapy (fig 2). The
disappearance of promoter methylation at E-cadherin was
associated with reversal of chronic active gastritis to inactive
gastritis in 14 patients, and to normal mucosa in one patient.
There were three unmethylated specimens which became
methylated after eradication therapy (fig 2). One showed a
histological change from chronic active gastritis to intestinal
metaplasia (fig 2). Specificity of E-cadherin methylation was
confirmed by DNA sequencing (fig 1C, 1D). Patients with or
without E-cadherin methylation after H pylori eradication did
not differ in mean age (50 (8) v 52 (11) years; p = 0.5).
Promoter methylation at E-cadherin at week 0 and
week 6 in group 2 patients
At week 0, chronic active gastritis was present in all
specimens. Promoter methylation at E-cadherin was present
in 47.5% (19/40) of the gastric mucosa specimens (examples
in fig 3A). Mean age of patients with positive and negative
methylation in their gastric mucosa was 53 (10) years and 43
(14) years, respectively (p = 0.05). At week 6, none of the
specimens showed inactive gastritis or normal gastric
epithelium. Promoter methylation at E-cadherin was observed
Figure 1 CpG island methylation
pattern at the E-cadherin gene in gastric
mucosa from patients with dyspepsia.
MW, molecular weight marker; U,
unmethylated band; M, methylated
band. (A) At week 0 before eradication
of Helicobacter pylori, methylation was
present in patient Nos 3, 5, and 6. (B)
At week 6 after eradication of H pylori,
methylation was not present in any
patient. (C) At week 0 before eradi-
cation of H pylori, the methylated
product was confirmed by sequencing
using the same methylated primer. The
unmethylated cytosines were converted
to thymidine (red colour) while the
methylated cytosines remained
unchanged (blue colour). (D) At week 6
after eradication of H pylori, the
methylated product was again
confirmed by sequencing using the
same methylated primer. No
methylated cytosine was seen.
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in 52.5% (21/40) of specimens (examples in fig 3B) which
showed no difference in methylation frequency compared
with week 0 (p = 0.5). The methylation status at E-cadherin at
week 0 and week 6 was confirmed by sequencing (fig 3C,
3D). Three specimens with negative methylation at week 0
became positive at week 6. One specimen with positive
methylation at week 0 became negative at week 6.
Promoter methylation at other genes at week 0 and
week 6 in 10 of the group 1 patients
The methylation pattern at week 0 and week 6 at these genes
are summarised in table 3. Disappearance of methylation was
not observed in these genes.
Analysis for the presence of concordant methylation
Each of the 10 patients had five additional antral biopsies
taken. Eight showed concordant methylation: four showed
concordant positive E-cadherin methylation (at least 4/5
biopsies were positive for E-cadherin methylation from each
of these patients) and four showed concordant negative
methylation (all five biopsies were negative for E-cadherin
methylation from each of these patients).
Immunostaining of E-cadherin
Immunostaining of gastric mucosae from group 1 and group
2 patients showed strong membranous staining in the gastric
epithelium, and there was no difference in staining between
pre- and post-H pylori eradication in group 1 patients.
Promoter methylation at E-cadherin in the intestinal
metaplasia specimens
In the second cohort of patients, among 19 H pylori negative
specimens, 63% (12) showed E-cadherin methylation. Among
the 22 H pylori positive specimens, 72.7% (16) of specimens
were methylated (p = 0.5).
DISCUSSION
Our study showed that by eradicating H pylori infection early
in the stage of chronic gastritis in patients without gastric
cancer, promoter methylation at E-cadherin disappeared in a
high proportion of patients.
The importance of the E-cadherin gene in gastric carcino-
genesis has been well demonstrated,5–7 and hence the
methylation pattern at E-cadherin before and after eradica-
tion of H pylori was of particular interest in our study. We
have also studied other genes which have been reported to be
methylated in patients with chronic gastritis.20 The genes that
we chose are involved in cell cycle regulation (p16), DNA
repair or protection (hMLH1, MGMT), and apoptosis (DAP
kinase).
In addition to the important role E-cadherin plays in
gastric cancer, we have also demonstrated in our previous
work that methylation of the E-cadherin promoter is
associated with gastric cancer and have generated a hypoth-
esis linking E-cadherin methylation, H pylori infection,
intestinal metaplasia, and gastric carcinogenesis.13 14 The
current study again showed that H pylori infection was
associated with E-cadherin methylation at the gastric mucosa
in dyspeptic subjects without gastric cancer. Despite the fact
that the role of E-cadherin methylation in the gastric
epithelium in these dyspeptic subjects in the future develop-
ment of gastric cancer remains uncertain, targeting epige-
netic changes that occur before the development of frank
malignancy as chemopreventive intervention may offer the
maximal impact. Hence the disappearance of E-cadherin
methylation in these dyspeptic patients may be important for
preventing future development of gastric cancer.
In the current study we observed that the disappearance of
E-cadherin methylation after H pylori eradication was
associated with a decrease in activity of chronic gastritis,
according to the Sydney classification. The underlying
mechanism of the reversal of the methylation process is still
uncertain. We postulate that this may relate to the decrease
in inflammation after H pylori eradication. It is well known
that promoter methylation is associated with chronic
inflammatory conditions, such as inflammatory bowel dis-
ease,22 23 oesophageal mucosa in patients with Barrett’s
oesophagitis,24 25 and in liver tissues in chronic hepatitis.26
We also observed in the current study that, in the presence of
Post-H pylori eradication
15
Chronic
inactive
gastritis
4
Normal
1 
Intestinal
metaplasia
2
Chronic
inactive
gastritis
14
Chronic
inactive
gastritis
4
Chronic
inactive
gastritis
1
Normal
19
22 19
3 15 4
E-cadherin methylation
Group 1: 41 patients (pre-H pylori eradication)
All showed chronic active gastritis
– –
–
+ +
+
Figure 2 Summary of the methylation
and histology status of the 41 patients in
group 1, before and after Helicobacter
pylori eradication.
Table 2 E-cadherin methylation in gastric mucosal
specimens before and after Helicobacter pylori
eradication
E-cadherin
methylated
E-cadherin
unmethylated
Before H pylori eradication 19 22
After H pylori eradication 7* 34
*E-cadherin was previously methylated in four patients but unmethylated
in three patients.
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intestinal metaplasia, E-cadherin methylation did not associ-
ate with the presence of H pylori infection. This supports the
fact that the presence of E-cadherin methylation relates to
the underlying chronic inflammatory condition. In contrast,
it has been reported that methylation dependent gene
silencing can be induced by interleukin 1b via the action of
nitric oxide.27 It has also been recently reported that H pylori
upregulates mRNA expression, promoter activity, and
enzyme activity of inducible spermine oxidase in human
gastric epithelial cells, resulting in DNA damage and
apoptosis.28 Thus the disappearance of methylation at the
stage of chronic gastritis may also be directly related to
abolishment of oxidative stress caused by H pylori. The
current observation is intriguing and will require further
extensive studies to confirm the underlying mechanism.
In addition, we also assessed the presence of concordant
methylation within the antrum from 10 patients. We found
80% concordant methylation status. This implies that the
possibility that the difference in E-cadherin methylation at
week 0 and week 6 was due to random biopsy errors is less
likely.
Despite the fact that we observed differences in E-cadherin
methylation pre- and post-H pylori eradication in gastric
mucosae, we did not observe any difference in immuno-
staining at E-cadherin in these specimens. We postulate
that this may be due to the fact that MSP is a very
sensitive method for detecting methylation. The sensitivity of
MSP was 1023 (results not shown). On the other hand,
Figure 3 CpG island methylation at
the E-cadherin gene in gastric mucosa
from patients with dyspepsia without
receiving Helicobacter pylori
eradication therapy. MW, molecular
weight marker; U, unmethylated band;
M, methylated band. (A) At week 0,
methylation was present in patient Nos
2, 5, and 6. (B) At week 6, methylation
was still present in patient Nos 2, 5,
and 6. C. At week 0, methylated
products were confirmed by sequencing
using the same methylated primer.
Methylated cytosines were seen. (D) At
week 6, methylated cytosines were still
observed after sequencing using the
same methylated primer.
Table 3 Promoter methylation at DAPK, MGMT, hMLH1,
OR beta, and p16 at week 0 and week 6 in 10 of the
group 1 patients
Week 0 (n = 10)
(No (%))
Week 6 (n = 10)
(No (%))
DAPK 2 (20) 1 (10)
MGMT 0 2 (20)
hMLH1 1 (10) 1 (10)
OR beta 6 (60) 5 (50)
p16 0 0
E-cadherin 5 (50) 2 (20)
DAPK, DAP kinase; MGMT, O6-methyl-guanine methyltransferase;
hMLH1, human Mut L homologue; OR beta, oestrogen receptor beta.
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immunohistochemical staining is a qualitative method, and
is not as sensitive as PCR in detecting subpopulations of cells
with gene methylation and hence downregulation of E-
cadherin. A large number of cells may be needed to be
methylated before this is reflected in expression by immu-
nostaining.
Methylation analysis at other genes was also performed in
10 pairs of pre- and post-H pylori eradicated specimens.
However, no difference in methylation at these genes was
observed. This could be due to the small sample size. On the
other hand, methylation frequencies in gastric mucosa at
DAPK, MGMT, hMLH1, and p16 genes were 41%, 18.7%,
10.9%, and 4.1%, respectively, according to Kang and
colleagues,20 which was not as high as that observed in
E-cadherin, and this may also account for the difference.
The current study corroborates the observation in a
prospective randomised controlled study from our group
showing that eradicating H pylori prevented gastric cancer in
patients with chronic gastritis but not in those with existing
precursor lesions, such as intestinal metaplasia.29 The current
study may partially explain the clinical observation. Whether
disappearance of E-cadherin methylation at the gastric
mucosa in dyspeptic patients can eventually prevent gastric
cancer development still requires further investigation.
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